Dowpharma Sharpens Focus on New Expression Systems
Smithfield Facility Will be Closed
Dowpharma, a business unit of The Dow Chemical Company, has announced plans to close its biopharmaceutical contract manufacturing facility in Smithfield, Rhode Island. Dowpharma will continue to develop its biopharmaceutical contract manufacturing business by building on promising new developments in protein and peptide expression technologies that will contribute significantly to the pharmaceutical industry's drive for accessible, affordable medicines.
"Biotechnology is a dynamic industry and demands agility," said Nick Hyde, business director, Dowpharma. "The decision to close the Smithfield facility, formerly owned by Collaborative BioAlliance (CBA), is driven by changes in the biotech industry specifically around mammalian cell culture technology. One of the reasons for our decision to purchase CBA in 2000 was a forecast of additional mammalian cell culture capacity needed to supply the market. Market conditions for this technology have not evolved to the point the industry anticipated just a few years ago. We've recognized this and have decided to sharpen our focus on areas where we can deliver truly differentiated value to our customers. Our emphasis will be on enabling technologies for the rapid process development and scale-up of client production processes for therapeutic proteins and peptides."
To enable this, Dow previously announced the consolidation of its process development capability at Dow's biotechnology center in San Diego and recently launched its Pseudomonas fluorescens expression technology for the production of recombinant proteins. This novel technology can increase cellular expression while maintaining critical solubility and activity characteristics of recombinant proteins. Also this year, Dowpharma announced a new peptides offering, including expression and purification strategies for cost effective manufacturing.
Dowpharma will also focus on plant-based systems, having made several recent announcements about its expanded offerings to the industry in antibody expression and peptide expression. "These offerings allow both rapid scale up and higher productivity for complex proteins," Hyde added.
"Dowpharma is committed to offering tailored solutions to our clients through our expanding technical portfolio and key partnerships with other companies. We will continue to invest in opportunities to become a long-term leader in biopharmaceutical manufacturing by using our science base and operational expertise to help bring affordable medicines to market faster," stated Hyde.
DuPont and The Dow Chemical Company announced that their boards of directors unanimously approved a definitive agreement under which the companies will combine in an all-stock merger of equals. The combined company will be named DowDuPont. The parties intend to subsequently pursue a separat ... more
Vertellus closed on its previously announced acquisition of The Dow Chemical Company’s Sodium Borohydride (“SBH”) business.
The acquisition expands Vertellus’ life sciences business, adding new process aids and synthesis capabilities to the company’s asset structure. With a state-of-art ... more
Vertellus has signed a definitive agreement to acquire the Sodium Borohydride (“SBH”) business, including associated assets, from the Dow Chemical Company. Vertellus is a portfolio company of Chicago-based private equity firm Wind Point Partners. Wind Point acquired Vertellus in partnersh ... more
With annual sales of $58 billion in 2008 and 46,000 employees worldwide, Dow is a diversified chemical company that combines the power of science and technology with the " Human Element ” to constantly improve what is essential to human progress. The Company delivers a broad range of produ ... more